Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Werewolf Therapeutics, Inc., a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies. Its lead product candidates are WTX-124, a conditionally activated Interleukin-2 INDUKINE molecule for the treatment of advanced solid tumors; and WTX-330, a conditionally activated Interleukin-12 INDUKINE molecule for the treatment of relapsed or refractory advanced or metastatic solid tumors or lymphoma. The company is also developing WTX-613, a conditionally activated interferon alpha INDUKINE molecule for the treatment of solid tumors and hematologic malignancies. Werewolf Therapeutics, Inc. was incorporated in 2017 and is headquartered in Cambridge, Massachusetts.

Werewolf Therapeutics, Inc.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

WATERTOWN, MASS., SEPT. 02, 2025 (GLOBE NEWSWIRE) -- WEREWOLF THERAPEUTICS, INC. (THE COMPANY OR WEREWOLF) (NASDAQ: HOWL), AN INNOVATIVE BIOPHARMACEUTICAL COMPANY PIONEERING THE DEVELOPMENT OF CONDITIONALLY ACTIVATED THERAPEUTICS ENGINEERED TO STIMULATE THE BODY'S IMMUNE SYSTEM FOR THE TREATMENT OF CANCER AND OTHER IMMUNE-MEDIATED CONDITIONS, TODAY ANNOUNCED THAT DANIEL J.

WEREWOLF THERAPEUTICS TO PARTICIPATE IN THE UPCOMING H.C. WAINWRIGHT 27TH ANNUAL GLOBAL INVESTMENT CONFERENCE

 WTX-124 PHASE 1/1B CLINICAL TRIAL ON TRACK FOR INTERIM DATA READOUT IN THE FOURTH QUARTER OF 2025, INCLUDING PATIENTS IN BOTH THE MONOTHERAPY AND COMBINATION EXPANSION ARMS OF CUTANEOUS MELANOMA AND RENAL CELL CARCINOMA   PLANNING TO ENGAGE WITH U.S. FOOD & DRUG ADMINISTRATION (FDA) IN THE SECOND HALF OF 2025 TO DISCUSS POTENTIAL REGISTRATIONAL PATHWAYS FOR WTX-124 IN ADVANCED OR METASTATIC CUTANEOUS MELANOMA   PHASE 1B/2 CLINICAL TRIAL OF WTX-330 IS ACTIVELY ENROLLING, WITH ANTICIPATED DETERMINATION OF DOSING REGIMEN BY THE END OF 2025   COMPANY ANNOUNCES WTX-1011, ITS FIRST INDUCER  T-CELL ENGAGER DEVELOPMENT CANDIDATE, TARGETING STEAP1  WATERTOWN, MASS., AUG. 14, 2025 (GLOBE NEWSWIRE) -- WEREWOLF THERAPEUTICS, INC. (THE COMPANY OR WEREWOLF) (NASDAQ: HOWL), AN INNOVATIVE BIOPHARMACEUTICAL COMPANY PIONEERING THE DEVELOPMENT OF CONDITIONALLY ACTIVATED THERAPEUTICS ENGINEERED TO STIMULATE THE BODY'S IMMUNE SYSTEM FOR THE TREATMENT OF CANCER AND OTHER IMMUNE-MEDIATED CONDITIONS, TODAY PROVIDED A BUSINESS UPDATE AND REPORTED FINANCIAL RESULTS FOR THE SECOND QUARTER ENDED JUNE30, 2025.

WEREWOLF THERAPEUTICS REPORTS SECOND QUARTER 2025 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE

WATERTOWN, MASS., JULY 09, 2025 (GLOBE NEWSWIRE) -- WEREWOLF THERAPEUTICS, INC. (THE COMPANY OR WEREWOLF) (NASDAQ: HOWL), AN INNOVATIVE BIOPHARMACEUTICAL COMPANY PIONEERING THE DEVELOPMENT OF CONDITIONALLY ACTIVATED THERAPEUTICS ENGINEERED TO STIMULATE THE BODY'S IMMUNE SYSTEM FOR THE TREATMENT OF CANCER AND OTHER IMMUNE-MEDIATED CONDITIONS, TODAY ANNOUNCED RANDI ISAACS, M.D., CHIEF MEDICAL OFFICER, WILL SPEAK AT THE UPCOMING KIDNEYCAN 7TH ANNUAL KIDNEY CANCER RESEARCH SUMMIT TAKING PLACE JULY 17-18 IN BOSTON, MASSACHUSETTS.

WEREWOLF THERAPEUTICS TO PARTICIPATE IN THE KIDNEYCAN 7TH ANNUAL KIDNEY CANCER RESEARCH SUMMIT

WATERTOWN, MASS., JUNE 12, 2025 (GLOBE NEWSWIRE) -- WEREWOLF THERAPEUTICS, INC. (THE COMPANY OR WEREWOLF) (NASDAQ: HOWL), AN INNOVATIVE BIOPHARMACEUTICAL COMPANY PIONEERING THE DEVELOPMENT OF CONDITIONALLY ACTIVATED THERAPEUTICS ENGINEERED TO STIMULATE THE BODY'S IMMUNE SYSTEM FOR THE TREATMENT OF CANCER AND OTHER IMMUNE-MEDIATED CONDITIONS, TODAY ANNOUNCED RANDI ISAACS, M.D.

WEREWOLF THERAPEUTICS TO PARTICIPATE IN THE BIO INTERNATIONAL CONVENTION

WATERTOWN, MASS., MAY 29, 2025 (GLOBE NEWSWIRE) -- WEREWOLF THERAPEUTICS, INC. (THE COMPANY OR WEREWOLF) (NASDAQ: HOWL), AN INNOVATIVE BIOPHARMACEUTICAL COMPANY PIONEERING THE DEVELOPMENT OF CONDITIONALLY ACTIVATED THERAPEUTICS ENGINEERED TO STIMULATE THE BODY'S IMMUNE SYSTEM FOR THE TREATMENT OF CANCER, TODAY ANNOUNCED THAT DANIEL J. HICKLIN, PH.D., PRESIDENT AND CHIEF EXECUTIVE OFFICER AND RANDI ISAACS, M.D., CHIEF MEDICAL OFFICER, BOTH OF WEREWOLF THERAPEUTICS, WILL PARTICIPATE IN A FIRESIDE CHAT AT4:20 PM EDTONTHURSDAY, JUNE 5, 2025, AT THE JEFFERIES GLOBAL HEALTHCARE CONFERENCE, TAKING PLACE ON JUNE 3-5, 2025.

WEREWOLF THERAPEUTICS TO PARTICIPATE IN THE UPCOMING JEFFERIES GLOBAL HEALTHCARE CONFERENCE

WATERTOWN, MASS., MAY 13, 2025 (GLOBE NEWSWIRE) -- WEREWOLF THERAPEUTICS, INC. (THE COMPANY OR WEREWOLF) (NASDAQ: HOWL), AN INNOVATIVE BIOPHARMACEUTICAL COMPANY PIONEERING THE DEVELOPMENT OF CONDITIONALLY ACTIVATED THERAPEUTICS ENGINEERED TO STIMULATE THE BODY'S IMMUNE SYSTEM FOR THE TREATMENT OF CANCER AND OTHER IMMUNE-MEDIATED CONDITIONS, TODAY ANNOUNCED SAMEER CHOPRA, M.D., PH.D., VICE PRESIDENT OF CLINICAL DEVELOPMENT, WILL SPEAK DURING THE HANSON WADE CYTOKINE-BASED DRUG DEVELOPMENT SUMMIT TAKING PLACE MAY 15-16 IN BOSTON, MASSACHUSETTS.

WEREWOLF THERAPEUTICS TO PARTICIPATE IN HANSON WADE'S 6TH ANNUAL CYTOKINE-BASED DRUG DEVELOPMENT SUMMIT

WTX-124 PHASE 1/1B CLINICAL TRIAL ON TRACK FOR DATA READOUTS AND INTERACTIONS WITH THE FDA IN THE SECOND HALF OF THE YEAR 

WEREWOLF THERAPEUTICS REPORTS FIRST QUARTER 2025 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE

- DATA REVEAL WTX-921 IS EFFICACIOUS IN A MOUSE COLITIS MODEL, RESULTING IN REDUCED TISSUE DAMAGE AND INFLAMMATORY CYTOKINE PRODUCTION -

WEREWOLF THERAPEUTICS PRESENTS NEW PRECLINICAL DATA FURTHER CHARACTERIZING ITS IL-10 INDUKINE MOLECULE, WTX-921, FOR THE TREATMENT OF INFLAMMATORY BOWEL DISEASE (IBD)AT AAI ANNUAL MEETING

WATERTOWN, MASS., MAY 05, 2025 (GLOBE NEWSWIRE) -- WEREWOLF THERAPEUTICS, INC. (THE COMPANY OR WEREWOLF) (NASDAQ: HOWL), AN INNOVATIVE BIOPHARMACEUTICAL COMPANY PIONEERING THE DEVELOPMENT OF CONDITIONALLY ACTIVATED THERAPEUTICS ENGINEERED TO STIMULATE THE BODY'S IMMUNE SYSTEM FOR THE TREATMENT OF CANCER AND OTHER IMMUNE-MEDIATED CONDITIONS, TODAY ANNOUNCED THAT MANAGEMENT WILL PARTICIPATE IN THE FOLLOWING UPCOMING INVESTOR CONFERENCES IN THE MONTH OF MAY:

WEREWOLF THERAPEUTICS TO PARTICIPATE IN UPCOMING INVESTOR CONFERENCES

WATERTOWN, MASS., APRIL 17, 2025 (GLOBE NEWSWIRE) -- WEREWOLF THERAPEUTICS, INC. (THE COMPANY OR WEREWOLF) (NASDAQ: HOWL), AN INNOVATIVE BIOPHARMACEUTICAL COMPANY PIONEERING THE DEVELOPMENT OF CONDITIONALLY ACTIVATED THERAPEUTICS ENGINEERED TO STIMULATE THE BODY'S IMMUNE SYSTEM FOR THE TREATMENT OF CANCER AND OTHER IMMUNE-MEDIATED CONDITIONS, TODAY ANNOUNCED THE APPOINTMENT OF STEVEN BLOOM AS CHIEF BUSINESS OFFICER. MR. BLOOM BRINGS MORE THAN 35 YEARS OF EXPERIENCE IN THE LIFE SCIENCES INDUSTRY LEADING TEAMS IN CORPORATE DEVELOPMENT, COMMERCIAL PLANNING, CORPORATE AFFAIRS, AND STRATEGIC CONSULTING.

Werewolf Therapeutics, Inc.

HOWL

Price

Financials Overview

Financial Reports

No items found.

Press Releases

Werewolf Therapeutics, Inc.

HOWL.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financials Overview

Financial Reports

No items found.

Press Releases

HOWL